{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:27:10Z","timestamp":1793395630718,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.addr.2023.114781","type":"journal-article","created":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T19:27:41Z","timestamp":1679340461000},"page":"114781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems"],"prefix":"10.1016","volume":"196","author":[{"given":"Antoine","family":"Hakim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Guido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Narsineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7437-7917","authenticated-orcid":false,"given":"Marianna","family":"Foldvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.114781_b0005","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/bjo.2005.081224","article-title":"The number of people with glaucoma worldwide in 2010 and 2020","volume":"90","author":"Quigley","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0010","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.addr.2023.114781_b0015","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1073\/pnas.0913141107","article-title":"Distal axonopathy with structural persistence in glaucomatous neurodegeneration","volume":"107","author":"Crish","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2023.114781_b0020","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.preteyeres.2011.11.002","article-title":"The molecular basis of retinal ganglion cell death in glaucoma","volume":"31","author":"Almasieh","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0025","unstructured":"D. Krizaj, What is glaucoma?, in: H. Kolb, E. Fernandez, R. Nelson (Eds.) Webvision: The Organization of the Retina and Visual System, Salt Lake City (UT), 1995."},{"key":"10.1016\/j.addr.2023.114781_b0030","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.addr.2023.114781_b0035","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.preteyeres.2004.06.001","article-title":"The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage","volume":"24","author":"Burgoyne","year":"2005","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0040","doi-asserted-by":"crossref","first-page":"875","DOI":"10.4103\/1673-5374.184448","article-title":"The intricacies of neurotrophic factor therapy for retinal ganglion cell rescue in glaucoma: a case for gene therapy","volume":"11","author":"Foldvari","year":"2016","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.addr.2023.114781_b0045","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.eye.6701574","article-title":"Circulation and axonal transport in the optic nerve","volume":"18","author":"Morgan","year":"2004","journal-title":"Eye"},{"key":"10.1016\/j.addr.2023.114781_b0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"Lusthaus","year":"2019","journal-title":"Med. J. Australia"},{"key":"10.1016\/j.addr.2023.114781_b0055","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3109\/1061186X.2015.1052073","article-title":"Recent developments in ocular drug delivery","volume":"23","author":"Chen","year":"2015","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2023.114781_b0060","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/wnan.1361","article-title":"Neuroprotective therapies in glaucoma: I Neurotrophic factor delivery","volume":"8","author":"Nafissi","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2023.114781_b0065","first-page":"3460","article-title":"Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats","volume":"41","author":"Quigley","year":"2000","journal-title":"Invest Ophth Vis Sci"},{"key":"10.1016\/j.addr.2023.114781_b0070","first-page":"676","article-title":"In vitro bioassay model for screening non-viral neurotrophic factor gene delivery systems for glaucoma treatment, Drug Deliv","volume":"6","author":"Chen","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.addr.2023.114781_b0075","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/archopht.1981.03930010635009","article-title":"Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage","volume":"99","author":"Quigley","year":"1981","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0080","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2217\/nnm.12.69","article-title":"Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma","volume":"7","author":"Alqawlaq","year":"2012","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.addr.2023.114781_b0085","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114781_b0090","unstructured":"FDA, What is Gene Therapy?, USA, 2018."},{"key":"10.1016\/j.addr.2023.114781_b0095","unstructured":"EMA, Advanced therapy medicinal products: Overview, 2022."},{"key":"10.1016\/j.addr.2023.114781_b0100","unstructured":"Human Gene Therapy for Neurodegenerative Diseases- Guidance for Industry, in: FDA (Ed.)USA, 2022."},{"key":"10.1016\/j.addr.2023.114781_b0105","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.addr.2023.114781_b0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2023.114781_b0115","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0120","doi-asserted-by":"crossref","unstructured":"N. Bessis, F. GarciaCozar, M. Boissier, Immune responses to gene therapy vectors: influence on vector function and effector mechanisms, Gene therapy, 11 (2004) S10-S17.","DOI":"10.1038\/sj.gt.3302364"},{"key":"10.1016\/j.addr.2023.114781_b0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti\u2013adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.addr.2023.114781_b0130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114781_b0135","doi-asserted-by":"crossref","first-page":"e52189","DOI":"10.1371\/journal.pone.0052189","article-title":"Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery","volume":"7","author":"Han","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114781_b0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ymthe.2004.09.022","article-title":"Biodistribution of rAAV vectors following intraocular administration: evidence for the presence and persistence of vector DNA in the optic nerve and in the brain","volume":"11","author":"Provost","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114781_b0145","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.addr.2023.114781_b0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1357-4310(98)01376-8","article-title":"Expanded-capacity adenoviral vectors\u2013the helper-dependent vectors","volume":"5","author":"Morsy","year":"1999","journal-title":"Mol. Med. Today"},{"key":"10.1016\/j.addr.2023.114781_b0155","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/hum.2021.29172.bfs","article-title":"After Sparring with Payers on Pricing, Bluebird Flies Out of Europe","volume":"32","author":"Philippidis","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0160","doi-asserted-by":"crossref","first-page":"e56661","DOI":"10.15252\/embr.202256661","article-title":"Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?: Can we avoid a catastrophic second valley of death?","author":"De Luca","year":"2023","journal-title":"EMBO Rep."},{"key":"10.1016\/j.addr.2023.114781_b0165","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","article-title":"Luxturna: FDA documents reveal the value of a costly gene therapy","volume":"24","author":"Darrow","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2023.114781_b0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay9648","article-title":"Efficacy and costs of spinal muscular atrophy drugs","volume":"12","author":"Darrow","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2023.114781_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2022.12.001","article-title":"First hemophilia B gene therapy approved: More than two decades in the making","volume":"31","author":"Herzog","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114781_b0180","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/gt.2017.66","article-title":"Will rising prices and budget constraints prevent patients from accessing novel gene therapies?","volume":"24","author":"Kent","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0185","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.aaf4770","article-title":"Paying for future success in gene therapy","volume":"352","author":"Orkin","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114781_b0190","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.gt.3301110","article-title":"Nonviral gene therapy: promises and challenges","volume":"7","author":"Li","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0195","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2023.114781_b0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jconrel.2015.12.012","article-title":"Non-viral gene therapy: Gains and challenges of non-invasive administration methods","volume":"240","author":"Foldvari","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114781_b0205","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1021\/acsnano.8b07858","article-title":"Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery","volume":"13","author":"Buck","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2023.114781_b0210","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/mgme.1999.2906","article-title":"Leber congenital amaurosis","volume":"68","author":"Perrault","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.addr.2023.114781_b0215","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1167\/iovs.07-0068","article-title":"Clinical and molecular genetics of Leber's congenital amaurosis: A multicenter study of Italian patients","volume":"48","author":"Simonelli","year":"2007","journal-title":"Invest. Ophth. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/IIO.0000000000000364","article-title":"Gene Therapies for the Treatment of Leber Hereditary Optic Neuropathy","volume":"61","author":"Sahel","year":"2021","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.addr.2023.114781_b0225","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/17469899.2022.2147927","article-title":"How could gene therapy change the way we treat age-related macular degeneration?","volume":"17","author":"Khan","year":"2022","journal-title":"Expert Rev. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0230","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ceo.13917","article-title":"Inherited retinal diseases: Therapeutics, clinical trials and end points-A review","volume":"49","author":"Georgiou","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0235","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1172\/JCI43085","article-title":"Glaucoma: genes, phenotypes, and new directions for therapy","volume":"120","author":"Fan","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2023.114781_b0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/bs.pmbts.2015.04.008","article-title":"Glaucoma Genes and Mechanisms","volume":"134","author":"Wiggs","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0245","first-page":"80","article-title":"The Pathway From Genes to Gene Therapy in Glaucoma: A Review of Possibilities for Using Genes as Glaucoma Drugs","volume":"6","author":"Borras","year":"2017","journal-title":"Asia-Pac. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0250","doi-asserted-by":"crossref","DOI":"10.1111\/vop.12858","article-title":"Looking into the future: Gene and cell therapies for glaucoma","author":"Komaromy","year":"2021","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0255","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1073\/pnas.95.7.3978","article-title":"Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells","volume":"95","author":"Di Polo","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.addr.2023.114781_b0260","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1167\/iovs.12-9483o","article-title":"Advances in Glaucoma Treatment and Management: Gene Therapy","volume":"53","author":"Borras","year":"2012","journal-title":"Invest. Ophth. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exer.2016.08.022","article-title":"A single gene connects stiffness in glaucoma and the vascular system","volume":"158","author":"Borras","year":"2017","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-1041-8","article-title":"Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor\/tropomyosin- related kinase receptor-B signaling","volume":"9","author":"Osborne","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2023.114781_b0275","doi-asserted-by":"crossref","unstructured":"R.G. Ellis-Behnke, Y.X. Liang, S.W. You, D.K.C. Tay, S.G. Zhang, K.F. So, G.E. Schneider, Nano neuro knitting: Peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision (vol 103, pg 5054, 2006), P Natl Acad Sci USA, 103 (2006) 7530-7530.","DOI":"10.1073\/pnas.0602514103"},{"key":"10.1016\/j.addr.2023.114781_b0280","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.preteyeres.2013.04.001","article-title":"Nanomedicines for back of the eye drug delivery, gene delivery, and imaging","volume":"36","author":"Kompella","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0285","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.nano.2014.05.010","article-title":"Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy","volume":"10","author":"Alqawlaq","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2023.114781_b0290","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.preteyeres.2010.08.002","article-title":"Applications of nanoparticles in ophthalmology","volume":"29","author":"Diebold","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24203805","article-title":"Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems","volume":"24","author":"Juliana","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2023.114781_b0300","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archopht.123.4.458","article-title":"Oxidative DNA damage in the human trabecular meshwork - Clinical correlation in patients with primary open-angle glaucoma","volume":"123","author":"Sacca","year":"2005","journal-title":"Arch. Ophthalmol.-Chic."},{"key":"10.1016\/j.addr.2023.114781_b0305","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1566523221666210423084233","article-title":"Gene Therapy in the Anterior Eye Segment","volume":"22","author":"Amador","year":"2022","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0310","doi-asserted-by":"crossref","first-page":"108482","DOI":"10.1016\/j.exer.2021.108482","article-title":"RNA therapeutics in ophthalmology - translation to clinical trials","volume":"205","author":"Gupta","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0315","doi-asserted-by":"crossref","first-page":"e1803239","DOI":"10.1002\/smll.201803239","article-title":"Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy","volume":"14","author":"Dillinger","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.addr.2023.114781_b0320","doi-asserted-by":"crossref","first-page":"118712","DOI":"10.1016\/j.lfs.2020.118712","article-title":"Small interfering RNAs (siRNAs) based gene silencing strategies for the treatment of glaucoma: Recent advancements and future perspectives","volume":"264","author":"Naik","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.addr.2023.114781_b0325","first-page":"712","article-title":"TGF-beta-induced IOP elevations are mediated by RhoA in the early but not the late fibrotic phase of open angle glaucoma","volume":"24","author":"Hill","year":"2018","journal-title":"Mol. Vis."},{"key":"10.1016\/j.addr.2023.114781_b0330","first-page":"32","article-title":"Gene transfer of dominant-negative RhoA increases outflow facility in perfused human anterior segment cultures","volume":"8","author":"Vittitow","year":"2002","journal-title":"Mol. Vis."},{"key":"10.1016\/j.addr.2023.114781_b0335","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ajpath.2012.02.030","article-title":"Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork","volume":"180","author":"Junglas","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.addr.2023.114781_b0340","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.exer.2008.01.013","article-title":"Extracellular matrix in the trabecular meshwork","volume":"86","author":"Acott","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0345","article-title":"Junyi Chen, miR-21-5p: A viable therapeutic strategy for regulating intraocular pressure","volume":"200","author":"Chen Tan","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0350","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1039\/D0TB02881A","article-title":"A miRNA stabilizing polydopamine nano-platform for intraocular delivery of miR-21-5p in glaucoma therapy","volume":"9","author":"Tan","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2023.114781_b0355","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12951-021-01199-3","article-title":"Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury","volume":"19","author":"Lou","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.addr.2023.114781_b0360","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.addr.2023.114781_b0365","series-title":"Physiology","author":"Sunderland","year":"2022"},{"key":"10.1016\/j.addr.2023.114781_b0370","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/mt.2013.217","article-title":"Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-adrenergic receptor 2, for lowering intraocular pressure","volume":"22","author":"Moreno-Montanes","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114781_b0375","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/mt.2013.216","article-title":"In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma","volume":"22","author":"Martinez","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114781_b0380","first-page":"1163","article-title":"Silencing of P2Y2 receptors reduces intraocular pressure in New Zealand rabbits, Brit","volume":"165","author":"Martin-Gil","year":"2012","journal-title":"J. Pharmacol."},{"key":"10.1016\/j.addr.2023.114781_b0385","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.879957","article-title":"From Bench to Bed: The Current Genome Editing Therapies for Glaucoma","volume":"10","author":"He","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.addr.2023.114781_b0390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.preteyeres.2018.08.003","article-title":"Gene therapy for visual loss: Opportunities and concerns","volume":"68","author":"Lee","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0395","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ymthe.2019.12.012","article-title":"Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9","volume":"28","author":"Wu","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2023.114781_b0400","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression - Results from the early manifest glaucoma trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch. Ophthalmol.-Chic."},{"key":"10.1016\/j.addr.2023.114781_b0405","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1706193114","article-title":"CRISPR-Cas9-based treatment of myocilin-associated glaucoma","volume":"114","author":"Jain","year":"2017","journal-title":"P Natl. Acad. Sci. USA"},{"key":"10.1016\/j.addr.2023.114781_b0410","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archopht.120.7.941","article-title":"Adenovirus-mediated gene therapy using human p21WAF-1\/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery","volume":"120","author":"Perkins","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0415","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/sj.gt.3302253","article-title":"Gene therapy using p21WAF-1\/Cip-1 to modulate wound healing after glaucoma trabeculectomy surgery in a primate model of ocular hypertension","volume":"11","author":"Heatley","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0420","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/aps.2009.23","article-title":"Adenovirus-mediated delivery of p27(KIP1) to prevent wound healing after experimental glaucoma filtration surgery","volume":"30","author":"Yang","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.addr.2023.114781_b0425","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/02713683.2015.1082184","article-title":"Evaluation of Adenovirus-Mediated Down-Regulation of Connective Tissue Growth Factor on Postoperative Wound Healing After Experimental Glaucoma Surgery","volume":"41","author":"Lim","year":"2016","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0430","first-page":"2502","article-title":"Cationic nano-copolymers mediated IKKbeta targeting siRNA to modulate wound healing in a monkey model of glaucoma filtration surgery","volume":"16","author":"Ye","year":"2010","journal-title":"Mol. Vis."},{"key":"10.1016\/j.addr.2023.114781_b0435","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1136\/bjophthalmol-2018-311937","article-title":"Targeted therapy for the post-operative conjunctiva: SPARC silencing reduces collagen deposition","volume":"102","author":"Seet","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0440","doi-asserted-by":"crossref","first-page":"21881","DOI":"10.1038\/srep21881","article-title":"Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis","volume":"6","author":"Yu-Wai-Man","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2023.114781_b0445","doi-asserted-by":"crossref","first-page":"690","DOI":"10.18240\/ijo.2022.05.02","article-title":"Exosome-mediated aptamer S58 reduces fibrosis in a rat glaucoma filtration surgery model","volume":"15","author":"Lin","year":"2022","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0450","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.exer.2010.05.016","article-title":"Neurotrophic factor delivery as a protective treatment for glaucoma","volume":"93","author":"Johnson","year":"2011","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7571-6_1","article-title":"Neurotrophic Factors: An Overview","volume":"1727","author":"Skaper","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2023.114781_b0460","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-7571-6_2","article-title":"Ocular Nerve Growth Factor (NGF) and NGF Eye Drop Application as Paradigms to Investigate NGF Neuroprotective and Reparative Actions","volume":"1727","author":"Tirassa","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.addr.2023.114781_b0465","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1113\/jphysiol.2008.156729","article-title":"Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina","volume":"586","author":"Weber","year":"2008","journal-title":"J. Physiol."},{"key":"10.1016\/j.addr.2023.114781_b0470","first-page":"409","article-title":"Tyrosine triple mutated AAV2-BDNF gene therapy in an inner retinal injury model induced by intravitreal injection of N-methyl-D-aspartate (NMDA)","volume":"26","author":"Shiozawa","year":"2020","journal-title":"Mol. Vis."},{"key":"10.1016\/j.addr.2023.114781_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113167","article-title":"Intravitreal application of AAV-BDNF or mutant AAV-CRMP2 protects retinal ganglion cells and stabilizes axons and myelin after partial optic nerve injury","volume":"326","author":"Chiha","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.addr.2023.114781_b0480","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1089\/hum.2017.069","article-title":"Design of a Novel Gene Therapy Construct to Achieve Sustained Brain-Derived Neurotrophic Factor Signaling in Neurons","volume":"29","author":"Osborne","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0485","article-title":"Significant changes in endogenous retinal gene expression assessed 1 year after a single intraocular injection of AAV-CNTF or AAV-BDNF","volume":"3","author":"LeVaillant","year":"2016","journal-title":"Mol. Ther.-Meth. Clin. D"},{"key":"10.1016\/j.addr.2023.114781_b0490","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1167\/iovs.11-8484","article-title":"Long-Term Rescue of Rat Retinal Ganglion Cells and Visual Function by AAV-Mediated BDNF Expression after Acute Elevation of Intraocular Pressure","volume":"53","author":"Ren","year":"2012","journal-title":"Invest. Ophth. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0495","doi-asserted-by":"crossref","DOI":"10.3390\/biom11040581","article-title":"Use of Gene Therapy in Retinal Ganglion Cell Neuroprotection: Current Concepts and Future Directions","volume":"11","author":"Rhee","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.addr.2023.114781_b0500","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1167\/iovs.05-0362","article-title":"Brain-derived neurotrophic factor gene delivery to muller glia preserves structure and function of light-damaged photoreceptors","volume":"46","author":"Gauthier","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0505","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1083\/jcb.200706181","article-title":"Axons of retinal ganglion cells are insulted in the optic nerve early in DBA\/2J glaucoma","volume":"179","author":"Howell","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.addr.2023.114781_b0510","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.preteyeres.2006.05.003","article-title":"Muller cells in the healthy and diseased retina","volume":"25","author":"Bringmann","year":"2006","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0515","article-title":"Astrocyte remodeling without gliosis precedes optic nerve Axonopathy","volume":"6","author":"Cooper","year":"2018","journal-title":"Acta Neuropathol. Com."},{"key":"10.1016\/j.addr.2023.114781_b0520","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/glia.22477","article-title":"New functions of Muller cells","volume":"61","author":"Reichenbach","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.addr.2023.114781_b0525","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1167\/iovs.05-1570","article-title":"Targeted transgene expression in Muller glia of normal and diseased retinas using lentiviral vectors","volume":"48","author":"Greenberg","year":"2007","journal-title":"Invest. Ophth. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0530","doi-asserted-by":"crossref","first-page":"e7467","DOI":"10.1371\/journal.pone.0007467","article-title":"A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Muller cells","volume":"4","author":"Klimczak","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114781_b0535","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.exer.2014.08.004","article-title":"Enhanced survival of retinal ganglion cells is mediated by Muller glial cell-derived PEDF","volume":"127","author":"Unterlauft","year":"2014","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0540","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s11064-012-0747-8","article-title":"Pigment Epithelium-Derived Factor Released by Muller Glial Cells Exerts Neuroprotective Effects on Retinal Ganglion Cells","volume":"37","author":"Unterlauft","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.addr.2023.114781_b0545","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejpb.2019.05.023","article-title":"The obstacle course to the inner retina: Hyaluronic acid-coated lipoplexes cross the vitreous but fail to overcome the inner limiting membrane","volume":"141","author":"Devoldere","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2023.114781_b0550","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.exer.2017.02.006","article-title":"Biological aspects of axonal damage in glaucoma: A brief review","volume":"157","author":"Tamm","year":"2017","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.22058","article-title":"The Morphology and Spatial Arrangement of Astrocytes in the Optic Nerve Head of the Mouse","volume":"516","author":"Sun","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.addr.2023.114781_b0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.06.003","article-title":"Glia-neuron interactions in the mammalian retina","volume":"51","author":"Vecino","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0565","doi-asserted-by":"crossref","unstructured":"F.M. Chen D-W, Retinal multipotent stem-cell derived \u201cMiEye\u201d spheroid 3D culture model for preclinical screening of non-viral gene delivery systems, Precision Nanomed., 1 (2018) 106\u2013123.","DOI":"10.29016\/180711.1"},{"key":"10.1016\/j.addr.2023.114781_b0570","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/1521-3773(20000602)39:11<1906::AID-ANIE1906>3.0.CO;2-Q","article-title":"Gemini surfactants","volume":"39","author":"Menger","year":"2000","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2023.114781_b0575","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/156652308783688491","article-title":"Gemini surfactants: A new family of building blocks for non-viral gene delivery systems","volume":"8","author":"Wettig","year":"2008","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0580","doi-asserted-by":"crossref","unstructured":"L. Narsineni, D.W. Chen, M. Foldvari, BDNF Gene Delivery to the Retina for Neuroprotection in Glaucoma by Integrin-binding and Immunoglobulin Superfamily-Cell Adhesion Peptide-conjugated Gemini Nanoplexes In Vivo, J Control Release, (submitted) (2022).","DOI":"10.1016\/j.jconrel.2023.05.033"},{"key":"10.1016\/j.addr.2023.114781_b0585","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114781_b0590","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jchemneu.2019.01.006","article-title":"UMSC-derived exosomes promote retinal ganglion cells survival in a rat model of optic nerve crush","volume":"96","author":"Pan","year":"2019","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.addr.2023.114781_b0595","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/sctm.16-0428","article-title":"Bone Marrow-Derived Mesenchymal Stem Cells-Derived Exosomes Promote Survival of Retinal Ganglion Cells Through miRNA-Dependent Mechanisms","volume":"6","author":"Mead","year":"2017","journal-title":"Stem Cell Transl Med"},{"key":"10.1016\/j.addr.2023.114781_b0600","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1167\/iovs.18-25310","article-title":"Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Promote Neuroprotection in a Genetic DBA\/2J Mouse Model of Glaucoma","volume":"59","author":"Mead","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0605","article-title":"TNF alpha-Mediated Priming of Mesenchymal Stem Cells Enhances Their Neuroprotective Effect on Retinal Ganglion Cells","volume":"61","author":"Mead","year":"2020","journal-title":"Invest Ophth Vis Sci"},{"key":"10.1016\/j.addr.2023.114781_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107899","article-title":"Therapeutic effects of mesenchymal stem cell-derived exosomes on retinal detachment","volume":"191","author":"Ma","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0615","first-page":"47","article-title":"Ocular drug delivery systems: An overview, World","volume":"2","author":"Patel","year":"2013","journal-title":"J. Pharmacol."},{"key":"10.1016\/j.addr.2023.114781_b0620","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":"Recent perspectives in ocular drug delivery","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114781_b0625","unstructured":"I.A.a.T.F. Patron, Importance of the Noncorneol Absorption Route in Topical Ophthalmic Drug Delivery, INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 26 (1985) 584-587."},{"key":"10.1016\/j.addr.2023.114781_b0630","doi-asserted-by":"crossref","unstructured":"L. Wang, M.B. Zhou, H. Zhang, The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye, Ophthalmol Ther, (2021).","DOI":"10.1007\/s40123-021-00365-y"},{"key":"10.1016\/j.addr.2023.114781_b0635","unstructured":"R.P. Shrewsbury, Applied Pharmaceutics in Contemporary Compounding, Fourth Edition, 2020."},{"key":"10.1016\/j.addr.2023.114781_b0640","unstructured":"j. loyd V. Allen, Nicholas G Popovich and Howard C. Ansel Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th Edition ed., Lippincott Williams & Wilkins, Baltimore, Md, 2005."},{"key":"10.1016\/j.addr.2023.114781_b0645","doi-asserted-by":"crossref","unstructured":"Y. Yu, D.W.Y. Chow, C.M.L. Lau, G.Q. Zhou, W. Back, J. Xu, S. Carim, Y. Chau, A bioinspired synthetic soft hydrogel for the treatment of dry eye, Bioeng Transl Med, (2021).","DOI":"10.1002\/btm2.10227"},{"key":"10.1016\/j.addr.2023.114781_b0650","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/ijo.IJO_646_17","article-title":"Anatomy of cornea and ocular surface","volume":"66","author":"Sridhar","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.addr.2023.114781_b0655","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular Drug Delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2023.114781_b0660","article-title":"Pharmacokinetic and Biosdistribution of Bamosiran in Human and Animal model, a Novel Treatment for Glaucoma","volume":"56","author":"Gonzalez","year":"2015","journal-title":"Invest. Ophth. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0665","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.10.10.5","article-title":"Six-Month In Vivo Safety Profiling of Topical Ocular AVV5-Decorin Gene Transfer","volume":"10","author":"Mohan","year":"2021","journal-title":"Transl. Vis. Sci. Techn."},{"key":"10.1016\/j.addr.2023.114781_b0670","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2020.07.004","article-title":"Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles","volume":"326","author":"Baran-Rachwalska","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114781_b0675","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/tvst.10.10.6","article-title":"Long-Term Safety and Tolerability of BMP7 and HGF Gene Overexpression in Rabbit Cornea","volume":"10","author":"Gupta","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.addr.2023.114781_b0680","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091472","article-title":"mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation","volume":"13","author":"Gomez-Aguado","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114781_b0685","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/fcp.12561","article-title":"Progress on ocular siRNA gene-silencing therapy and drug delivery systems","volume":"35","author":"Jiang","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.addr.2023.114781_b0690","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/bs.pmbts.2015.06.010","article-title":"Neuroinflammation in Glaucoma and Optic Nerve Damage","volume":"134","author":"Mac Nair","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0695","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11095-008-9745-6","article-title":"Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina","volume":"26","author":"Kim","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2023.114781_b0700","doi-asserted-by":"crossref","first-page":"e0241006","DOI":"10.1371\/journal.pone.0241006","article-title":"The effects of PEGylation on LNP based mRNA delivery to the eye","volume":"15","author":"Ryals","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114781_b0705","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000479157","article-title":"Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases","volume":"58","author":"Peng","year":"2017","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.addr.2023.114781_b0710","first-page":"E1","article-title":"Suprachoroidal Injection Update: A novel drug delivery method with potential applications in gene therapy and ocular oncology","volume":"16","author":"Barakat","year":"2019","journal-title":"Retin. Physician"},{"key":"10.1016\/j.addr.2023.114781_b0715","article-title":"Restoration of RPGR expression in vivo using CRISPR\/Cas9 gene editing","author":"Gumerson","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0720","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2021.06.030","article-title":"In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles","volume":"336","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2023.114781_b0725","doi-asserted-by":"crossref","DOI":"10.1038\/s41434-021-00233-1","article-title":"Proteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina","author":"Ding","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0730","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.9.13.21","article-title":"Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium\/Choroid in Rabbits","volume":"9","author":"Kansara","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.addr.2023.114781_b0735","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/IJG.0000000000001451","article-title":"Evolving Guidelines for Intracameral Injection","volume":"29","author":"Liebmann","year":"2020","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.addr.2023.114781_b0740","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13060901","article-title":"Distribution of Gold Nanoparticles in the Anterior Chamber of the Eye after Intracameral Injection for Glaucoma Therapy","volume":"13","author":"Sonntag","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114781_b0745","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1167\/iovs.09-3847","article-title":"Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys","volume":"51","author":"Buie","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0750","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.gt.3303074","article-title":"Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2\/8","volume":"15","author":"Natkunarajah","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0755","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/17425247.2016.1201059","article-title":"Application of lipid nanoparticles to ocular drug delivery","volume":"13","author":"Battaglia","year":"2016","journal-title":"Expert Opin. Drug Del."},{"key":"10.1016\/j.addr.2023.114781_b0760","article-title":"Front or Back?: Intracameral vs. Intravitreal Injection of Bevacizumab for Neovascular Glaucoma","volume":"54","author":"Puthenparambil","year":"2013","journal-title":"Invest. Ophth. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0765","doi-asserted-by":"crossref","unstructured":"R.G. Stanley, Ocular clinical pharmacology, in: S.W.P. JILL E MADDISON, DAVID B CHURCH (Ed.) Small Animal Clinical Pharmacology2008, pp. 557\u2013573.","DOI":"10.1016\/B978-070202858-8.50027-0"},{"key":"10.1016\/j.addr.2023.114781_b0770","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1097\/ICO.0b013e318206c893","article-title":"Gene Transfer Using Micellar Nanovectors Inhibits Corneal Neovascularization In Vivo","volume":"30","author":"Iriyama","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.addr.2023.114781_b0775","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/gt.2009.50","article-title":"Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model","volume":"16","author":"Yoon","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0780","first-page":"310","article-title":"Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization","volume":"16","author":"Chen","year":"2010","journal-title":"Mol. Vis."},{"key":"10.1016\/j.addr.2023.114781_b0785","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.gt.3302442","article-title":"Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model","volume":"12","author":"Yoon","year":"2005","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0790","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/02713683.2013.779720","article-title":"Direct Comparison of Administration Routes for AAV8-mediated Ocular Gene Therapy","volume":"38","author":"Igarashi","year":"2013","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.addr.2023.114781_b0795","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1172\/JCI65654","article-title":"Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration","volume":"125","author":"Byrne","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.addr.2023.114781_b0800","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/gt.2011.163","article-title":"Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9","volume":"19","author":"Dalkara","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0805","first-page":"465","article-title":"Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer","volume":"9","author":"Zhang","year":"2003","journal-title":"Mol. Vis."},{"key":"10.1016\/j.addr.2023.114781_b0810","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/gt.2008.185","article-title":"Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV","volume":"16","author":"Singh","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0815","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/gt.2016.14","article-title":"Inducible scAAV2.GRE.MMP1 lowers IOP long-term in a large animal model for steroid-induced glaucoma gene therapy","volume":"23","author":"Borras","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0820","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1016\/j.cell.2021.06.031","article-title":"Preservation of vision after CaMKII-mediated protection of retinal ganglion cells","volume":"184","author":"Guo","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.addr.2023.114781_b0825","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1167\/iovs.08-3013","article-title":"Effect of CNTF on retinal ganglion cell survival in experimental glaucoma","volume":"50","author":"Pease","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2023.114781_b0830","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/104303403321070801","article-title":"Delivery of ciliary neurotrophic factor via lentiviral-mediated transfer protects axotomized retinal ganglion cells for an extended period of time","volume":"14","author":"van Adel","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.addr.2023.114781_b0835","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1038\/s41467-022-34443-x","article-title":"Ciliary neurotrophic factor-mediated neuroprotection involves enhanced glycolysis and anabolism in degenerating mouse retinas","volume":"13","author":"Do Rhee","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114781_b0840","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.addr.2023.114781_b0845","first-page":"799","article-title":"Adeno-associated virus mediated SOD gene therapy protects the retinal ganglion cells from chronic intraocular pressure elevation induced injury via attenuating oxidative stress and improving mitochondrial dysfunction in a rat model","volume":"8","author":"Jiang","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.addr.2023.114781_b0850","doi-asserted-by":"crossref","first-page":"5614","DOI":"10.1038\/s41467-020-19436-y","article-title":"Protrudin functions from the endoplasmic reticulum to support axon regeneration in the adult CNS","volume":"11","author":"Petrova","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2023.114781_b0860","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41419-021-04068-x","article-title":"BCLX(L) gene therapy moderates neuropathology in the DBA\/2J mouse model of inherited glaucoma","volume":"12","author":"Donahue","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2023.114781_b0865","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1006\/mthe.2002.0608","article-title":"Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model","volume":"5","author":"McKinnon","year":"2002","journal-title":"Mol. Ther."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:36:27Z","timestamp":1759210587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":172,"alternative-id":["S0169409X23000960"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.114781","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.114781","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114781"}}